1,463 results on '"Moliterno, David"'
Search Results
302. Year 1: A Short Look Back and a Long Look Forward
303. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials
304. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients
305. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
306. Bifurcation Stenting Techniques and Outcomes in Patients With Stable Coronary Artery Disease
307. PATTERNS OF ADHERENCE TO DUAL ANTIPLATELET THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING COMPLEX PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE PARIS REGISTRY
308. IMPACT OF AGE ON THE MODES OF DUAL ANTIPLATELET THERAPY CESSATION: ANALYSIS FROM THE PARIS (PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS) REGISTRY
309. Potential Hazards of Adding Nonsteroidal Anti-inflammatory Drugs to Antithrombotic Therapy After Myocardial Infarction
310. Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
311. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
312. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
313. Trade-off ofmyocardial infarction vs. bleeding types onmortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
314. American College of Cardiology Annual Scientific Session 2010: Update in Interventional Cardiology
315. Dual Antiplatelet Therapy: Is It Time to Cut the Cord With Aspirin?
316. Antiplatelet Agents
317. Unstable Angina Trials: PARAGON, PURSUIT, PRISM, PRISM-PLUS, and GUSTO-IV
318. TCT-490 Frequency And Impact Of Nuisance Bleeding On Adverse Events After Percutaneous Coronary Intervention: 2-Year Results From The Patterns Of Non-Adherence To Antiplatelet Regimens In Stented Patients (PARIS) Registry
319. Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)
320. TCT-501 Dual Antiplatelet Therapy Interruption For Surgery: Insights From The PARIS (Patterns Of Non-adherence To Anti-Platelet Regiments In Stented Patients) Registry
321. Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
322. The impact of left anterior descending coronary artery length on survival following myocardial infarction: To the apex and beyond
323. Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes
324. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact
325. ASSOCIATIONS BETWEEN DUAL ANTIPLATELET THERAPY CESSATION AND MACE DUE TO STOPPING ONE OR BOTH DRUGS: INSIGHTS FROM THE PARIS REGISTRY
326. CLOPIDOGREL WITH AND WITHOUT PROTON PUMP INHIBITOR USE: A PARIS REGISTRY ANALYSIS
327. ASSOCIATIONS BETWEEN DIFFERENT MODES OF DAPT CESSATION AND MAJOR ADVERSE EVENTS AT 6 MONTHS AND BEYOND: INSIGHTS FROM THE PARIS REGISTRY
328. TEMPORAL ASSOCIATIONS BETWEEN TIME AFTER PERCUTANEOUS CORONARY INTERVENTION, DUAL ANTIPLATELET THERAPY CESSATION AND STENT THROMBOSIS IN THE CONTEMPORARY PCI ERA: INSIGHTS FROM THE PARIS REGISTRY
329. SHORTER HOSPITAL STAYS AND OUTCOMES AFTER NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
330. High‐risk coronary anatomy versus high‐risk physiology as outcome predictors in acute coronary syndromes
331. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial
332. Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)
333. Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery
334. Value of High-Sensitivity Troponin in Assessing the Extent of Benefit Provided by Ticagrelor Versus Clopidogrel in Non–ST-Segment Elevation Acute Coronary Syndromes
335. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes
336. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study
337. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy
338. JACC: Cardiovascular Interventions Top Reviewers 2021.
339. Evolving our learning and application of knowledge to practice—The ongoing challenges of time and cost in interventional cardiology.
340. Effectiveness of PCI for non-acute coronary artery disease
341. The Evolving Role of Cardiac Troponin in the Evaluation of Cardiac Disorders
342. Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years
343. Tissue necrosis factor α and targeting its receptor in ischaemic heart disease
344. Remote ischemic preconditioning in elective percutaneous coronary intervention does not protect myocardium nor mobilize endothelial progenitor cells
345. EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBITORS IN COMBINATION WITH VORAPAXAR, A PLATELET THROMBIN-RECEPTOR ANTAGONIST, AMONG PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE TRACER TRIAL
346. FREQUENCY AND IMPACT OF SINGLE VERSUS DUAL ANTIPLATELET CESSATION ON ADVERSE CARDIAC EVENTS: RESULTS FROM THE PARIS REGISTRY
347. INCIDENCE AND PREDICTORS OF SUDDEN CARDIAC DEATH AFTER HOSPITALIZATION FOR NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: AN ANALYSIS FROM THE TRACER TRIAL
348. PREDICTORS OF DUAL ANTIPLATELET THERAPY NON-ADHERENCE AFTER PCI: ONE-YEAR INSIGHTS FROM THE PARIS REGISTRY
349. Documento de consenso de expertos. Tercera definición universal del infarto de miocardio
350. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.